We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
PAZOPANIB ADVZ (Boucher & Muir Pty Ltd)
Product name
PAZOPANIB ADVZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
129 (255 working days)
Active ingredients
pazopanib hydrochloride
Registration type
New generic medicine
Indication
PAZOPANIB ADVZ is indicated for the treatment of:
- Advanced and/or metastatic renal cell carcinoma (RCC)
- Advanced (unresectable and/or metastatic) soft tissue sarcoma (STS) in patients who,unless otherwise contraindicated, have received prior chemotherapy including ananthracycline treatment. The Phase III trial population excluded patients with gastrointestinal stromal tumour(GIST) or adipocytic soft tissue sarcoma.